SeaStar Medical Holding Corp
SeaStar Medical Holding Corp is a U.S.-based medical device company focused on therapies that treat acute and chronic kidney injury through selective cytopheretic devices. Its commercial product, QUELIMMUNE, is used in pediatric patients, while the company also develops an adult SCD program and next-generation device candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaCommercialized QUELIMMUNE devices sold for pediatric use in hospital settings.
Adult SCD and next-generation SCD programs under clinical and regulatory development.
Government grants and potential partner payments that support research and development.
Asiakkaat
SeaStar Medical sells primarily to pediatric hospital customers that use QUELIMMUNE in clinical care settings. Its development pipeline is aimed at hospitals and clinicians treating adult patients with serious kidney injury, with future commercialization dependent on regulatory approval and adoption by medical centers.
Hospitals and pediatric care centers buying QUELIMMUNE for treated pediatric patients.
Sites and institutions supporting adult SCD studies and regulatory development.
Public and other grant sources funding research, development, and operations.
Companies or institutions that may provide license, collaboration, or strategic payments.
Strategia
The company’s near-term strategy is to expand QUELIMMUNE adoption in pediatric hospitals and build a repeatable commercial base. In parallel, it is advancing the adult SCD program through pivotal clinical development and seeking additional capital, collaborations, and grants to support the pipeline.
Commercial sales are the first scalable product revenue source.
Adult approval would materially expand the market beyond pediatrics.
Development and commercialization require ongoing capital support.
Maantiede
SeaStar Medical is headquartered in the United States and its reported commercial activity is centered there. The company’s customer base, clinical development work, and regulatory interactions are also U.S.-based, so its business is tied closely to FDA approval pathways and U.S. hospital adoption.
Riskit
SeaStar Medical faces substantial financing and going-concern risk because it is still building commercial revenue while funding clinical development. Its business also depends on regulatory outcomes, hospital adoption, and successful execution of clinical trials, all of which can delay or prevent future product sales.
- Going concern and financing dependenceVaikutus: KriittinenTodennäköisyys: Korkea
The company states it needs additional capital to fund operations and may need restructuring if financing is unavailable.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Adult SCD commercialization depends on successful clinical development and FDA approval.
Kohdistuu: Adult SCD pipeline
- Clinical development riskVaikutus: KorkeaTodennäköisyys: Korkea
Preclinical and pivotal trial programs are costly and may fail to demonstrate efficacy or safety.
Kohdistuu: Adult and next-generation SCD programs
- Commercial rollout riskVaikutus: Korkea
QUELIMMUNE sales depend on hospital adoption and can fluctuate quarter to quarter.
Kohdistuu: Pediatric hospital sales
Kirjanpito
Harkinnanvaraiset erätCommercial revenue is newly recognized and likely point-in-time based on shipment or delivery terms.
Vaikutus: Affects reported revenue timing and quarterly comparability
Historical revenue has been primarily from government and other grants.
Vaikutus: Can create non-product revenue that is less repeatable
Clinical and medical affairs employees receive stock-based compensation.
Vaikutus: Raises operating expenses and affects loss metrics
Management must assess funding sufficiency and disclosure of substantial doubt.
Vaikutus: Influences financial statement presentation and risk disclosure
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Waystar Holding Corp.
WAY · Services-Computer Integrated Systems Design
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
Shuttle Pharmaceuticals Holdings, Inc.
SHPH · Pharmaceutical Preparations
Seafarer Exploration Corp
SFRX · Services-Amusement & Recreation Services
Seafarer Exploration Corp is a U.S.-based public company organized around the acquisition, development, and commercialization of marine-related business opportunities.
Kestra Medical Technologies, Ltd
KMTS · Surgical & Medical Instruments & Apparatus
Kestra Medical Technologies is a U.S.-based commercial-stage medical device company focused on wearable cardiac monitoring and therapeutic intervention.
Päivitetty: 24.9.2026